2018-001582-16
Efficacy of Albumin Replacement and Balanced Crystalloid Solutions in Septic Shock (the ALBIOSS-BALANCED trial): a 2-by-2 factorial, investigator-initiated, open-label, multicenter, randomized, controlled trial.

W06 Ricerca farmaco

281

Titolo/oggetto del contratto di sperimentazione

Efficacy of Albumin Replacement and Balanced Crystalloid Solutions in Septic Shock (the ALBIOSS-BALANCED trial): a 2-by-2 factorial, investigator-initiated, open-label, multicenter, randomized, controlled trial.

date_time

2021-11-26 10:47:00

Codice EUDRACT

2018-001582-16

Principal investigators

Codice del protocollo del promotore

RF-2016-02361583 (ALBIOSS-BALANCED Trial)

Data di nullaosta

13-10-2021

Data sottoscrizione del contratto

09-11-2021

Data di chiusura

Budget

0,00

Rimborsi

0,00

Totale

0,00

note

Data di inserimento

Utente inserimento

Data ultima modifica

22-02-2022 09:36:53

Utente ultima modifica

{"id":"735","name":"Fornasiero Gaia"}

Pincipal investigators

parent_id

Nome Unità Operativa

Anestesia e Rianimazioni di Rimini

Nome principal investigator

Jonathan Montomoli

CV Principal investigator

/documenti/W06/20231207/Montomoli_Jonathan_CV.pdf

2018-001582-16 Efficacy of Albumin Replacement and Balanced Crystalloid Solutions in Septic Shock (the ALBIOSS-BALANCED trial): a 2-by-2 factorial, investigator-initiated, open-label, multicenter, randomized, controlled trial.

W06 Ricerca farmaco

Pincipal investigators

2018-001582-16
Efficacy of Albumin Replacement and Balanced Crystalloid Solutions in Septic Shock (the ALBIOSS-BALANCED trial): a 2-by-2 factorial, investigator-initiated, open-label, multicenter, randomized, controlled trial.